Aligos Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 25, 2025, details the outcomes of Aligos Therapeutics, Inc.'s Annual Meeting of Stockholders. The company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Capital Market under the symbol ALGS.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Corporate Actions
Stockholders approved several significant amendments at the Annual Meeting:
- Equity Plan Amendment: The 2020 Incentive Award Plan was amended to increase the number of shares reserved for issuance by 1,000,000 shares. The total reserved shares now include 177,072 existing shares, shares from the 2018 Plan that become available, an annual increase mechanism (5% of outstanding shares or pre-funded warrants), and the new 1,000,000 share addition.
- Authorized Share Increase: The Company's Amended and Restated Certificate of Incorporation was amended to increase authorized voting common stock from 20,000,000 to 100,000,000 shares.
- Non-Voting Stock Increase: Authorized non-voting common stock was increased from 800,000 to 15,800,000 shares.
- Board Elections: Three Class II directors (K. Peter Hirth, Heather Preston, and Margarita Chavez) were elected to serve until the 2028 annual meeting.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting Results and Management Commentary
As of the record date (April 28, 2025), 5,314,801 shares of voting common stock were outstanding. The voting tabulation for the five proposals was as follows:
| Proposal | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (Class II) | 2,161,021 - 2,161,429 | 6,698 - 7,106 | N/A | 1,268,587 |
| Ratification of Auditor | 3,429,953 | 4,968 | 1,793 | 0 |
| 2020 Plan Amendment | 1,928,200 | 238,399 | 1,528 | 1,268,587 |
| Increase Voting Common Stock | 2,938,972 | 392,536 | 105,206 | 0 |
| Increase Non-Voting Common Stock | 2,920,916 | 410,528 | 105,270 | 0 |
The filing does not provide specific management commentary, risk factors, or guidance beyond the description of the approved amendments and the incorporation by reference of the Proxy Statement.
Key Facts for Investor Verification
- Verify the total number of shares currently outstanding to assess the dilution impact of the 1,000,000 share increase to the 2020 Plan and the 80,000,000 share increase to authorized voting stock.
- Review the definitive Proxy Statement (filed April 28, 2025) for detailed terms of the 2020 Plan Amendment and the annual increase mechanism.
- Confirm the current status of the 2018 Equity Incentive Plan shares that may become available for issuance under the 2020 Plan.
- Monitor future filings for the actual issuance of shares under the amended plan to understand the timing of potential dilution.